HR+/HER2-low breast cancer
Oncology · 2026–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| trastuzumab deruxtecan Treatment of adult patients with hormone receptor positive (HR-positive) human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow unresectable… | Mar 2026 | Not recommended | input received Metastatic Breast Cancer Action Australia · Rare Cancers Australia |
Who spoke
Metastatic Breast Cancer Action Australia · Rare Cancers Australia
What the PBS pays
$99M in government benefit over 2024–25, across 9,999 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| trastuzumab deruxtecan | $98.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| trastuzumab deruxtecanTrastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) | TA1112 | terminated | 2025-11 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.